Xanthene derivatives are an important class of heterocyclic compounds with a wide spectrum of pharmacological activities. In our previous investigations, we found the good antiproliferative activity of two xanthene derivatives, with minimal toxicity investigated by in vitro tests. In this study, we tested the interaction of compound 1 (powerful potent antiproliferative compound) with calf thymus DNA (CT-DNA) under physiological conditions by spectrophotometric titration. The probable prediction of binding and the type of interaction forces involved in the arrangement between xanthene derivatives and CT-DNA were explored also through molecular docking studies. The results indicated that compound 1 interacts with CT-DNA by grove binding. The binding constant was found to be 2.5 ∙ 10 4 M −1 indicating the non-covalent binding of compound 1 to CT-DNA. Docking study results proposed possible binding modes, with binding energies of −9.39 and −8.65 kcal mol −1 for compounds 1 and 2, respectively, which supported previously obtained in vitro results for antiproliferative activity. In addition to experimental investigation, density functional theory (DFT) calculation with B3LYP/6-31G*, B3LYP/6-31G**, and B3LYP/6-31+G* levels of theories was performed on compounds 1 and 2 to obtain optimised geometry, spectroscopic and electronic properties. These studies could help in understanding the mechanisms of toxicity, resistance, side effects of xanthene derivatives, and their binding action mechanism to DNA

This work aimed to describe the synthesis and characterisation of two anionic Ru(III) complexes of the general formula Na[Ru - Cl 2 ( N -4-Cl-Ph-salim) 2 ] and Na[RuCl 2 ( N -3-Br-Ph-salim) 2 , their associated ligands, and determine their antioxidant activity. The ligands N- 4-Cl-phenylsalicylidenimine ( N -4-Cl-Ph-salimH, HL a ) and N- 3-Br-phenylsalicylidenimine ( N -3-Br-Ph-salimH, HL b ), Schiff bases, were synthesised from salicylaldehyde and chloroaniline or bromoaniline. The compounds were characterised us - ing IR spectroscopy and ESI ToF mass spectrometry. The following was confirmed: coordination of ligands on the Ru(III) centre, the molecular formulas, and the corresponding M − ions: [C 26 H 18 N 2 O 2 Cl 4 Ru] − ion, (m/z: 631.9173) and [C 26 H 18 N 2 O 2 Cl 2 Br 2 Ru] − ion, (m/z: 719.8283). The antioxidant activity was determined by the ABTS (2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) and DPPH (1,1-diphenyl-2-picrylhydrazyl) assays. In contrast to the ligands, both complexes proved to be strong scaven - gers of the ABTS and DPPH radicals with IC 50 (half maximal inhibitory concentration) values comparable to those of Trolox. As such, they present valuable candidates for further research related to their biological properties.

Two tetraketone derivatives, one previously reported and one novel, were synthesized, whose structures have been confirmed by elemental analyses, NMR, HPLC-MS, and IR spectroscopy. The crystal structures of synthesized tetraketones were determined using X-ray single-crystal diffraction. To analyze the molecular geometry and compare with experimentally obtained X-ray crystal data of synthesized compounds 1 (2,2'-((4-nitrophenyl)methylene)bis(5,5-dimethylcyclohexane-1,3-dione)) and 2 (2,2'-((4-hydroxy-3-methoxy-5-nitrophenyl)methylene)bis(5,5-dimethylcyclohexane-1,3-dione)), DFT calculations were performed with the standard 6-31G*(d), 6-31G**, and 6-31+G* basis sets. The calculated HOMO-LUMO energy gap for compound 1 was 4.60 eV and this value indicated that compound 1 is chemically more stable compared to compound 2 whose energy gap was 3.73 eV. Both compounds' calculated bond lengths and bond angles were in very good accordance to experimental values determined by X-ray single-crystal diffraction.

This article reports on an investigation into the ability of SiO2–Ta2O5 as a new sorbent for simultaneous preconcentration of Cd(ii), Co(ii), Cr(iii), Cu(ii), Fe(iii), Mn(ii), Ni(ii) and Pb(ii) ions from water by the column method and the parameters involved in this process.

This article reports on an investigation into the ability of SiO2–Ta2O5 as a new sorbent for simultaneous preconcentration of Cd(ii), Co(ii), Cr(iii), Cu(ii), Fe(iii), Mn(ii), Ni(ii) and Pb(ii) ions from water by the column method and the parameters involved in this process.

A phenotypic was performed against HR leukaemia cell lines with a tailored compound library of 3707 approved drugs and pharmacologically active compounds. studies. OC potently induced autophagy in SK-BR-3 by upregulation of LCA/B, Atg-3, Atg-7, Atg-16L within 6 – 12 hour treatment. OC had no effect on the viability of the non-tumorigenic MCF-12A and RSC 96 cells. In vivo , 5 – 10 mg/kg oral/ip dose range of OC potently inhibited 65% – 90% tumour growth both BT-474 and MDA-MB-231 BC cells xenograft models. This was further confirmed by significant reductions of Ki-67, CD31in treated animal tumours by IHC. Conclusion Collectively, these promising results suggest that OC is a unique dual Met/HER2 inhibitory lead entity with excellent therapeutic potential to control breast malignancies with aberrant Met or HER2 activity.

Introduction Since the discovery and clinical success of the platinum(II) anticancer drug, cisplatin, researchers are putting much effort to develop more efficient metal-based therapeutic compounds, with fewer side-effects and greater cytoselectivity. Ruthenium complexes arose as promising anticancer agents, due to the success of some ruthenium drug candidates in clinical trials. Here we report comparison of in vitro cytotoxic activity and mechanisms of action of cisplatin and four newly synthesised ruthenium(III) complexes with bidentate anionic schiff base derived from 5-methylsalicilaldehyde and methylamine: (complexes 1– 4). Material and methods Cytotoxicity was tested on four human cancer cell lines (K562, A549, EA.hy926, MDA-MB231) and one human non-tumour cell line (MRC-5), by MTT assay. Being the most cytotoxic of all four tested complexes, complex 1 (C1) (Na[RuLCl2], L=N-propyl-5-chlorosalicideniminato) is selected for further analyses of molecular mechanisms underlying its activity toward MDA-MB231 cells. Results and discussions The average IC50 values were in the low micromolar range 2–23 µM, depending on cell line. Investigated complexes displayed an apparent cytoselective profile, as they reduced the viability of tested tumour cell lines more efficiently than of the non-tumour MRC-5 cells. Cisplatin resistant MDA-MB231 cells showed to be ten times more sensitive to C1 (IC50=2 µM) than to cisplatin. 24 hour treatment of MDA-MB231 cells with IC50 values of C1 and cisplatin induced minor cell cycle alterations, while 48 hour treatment induced substantial accumulation of cells in Sub-G1 region, up to 22.4% (C1) and 86.4% (cisplatin), versus control 4.8%. Acridine orange/ethidium bromide dual staining confirmed the Annexin V-FITC/PI assay results of notable reduction in cell number after the treatment with C1 and cisplatin. While cisplatin-treated cells prominently die of necrosis, C1-treated cells after 24 hour treatment show apoptotic morphology, but after prolonged treatment, necrosis becomes predominant. Decrease in the intracellular levels of reactive oxygen species was comparable in the cisplatin-treated and C1-treated cells, with cisplatin displaying more conspicuous effects at higher dose. C1 entered the cells more efficiently compared to cisplatin. Intracellular C1 concentration after 4 hour treatment exceeded that of cisplatin by 7.8 times approximately. Conclusion Present study pointed out interesting activity of this type of ruthenium(III) complex and need for further biological studies and its chemical structure optimisation.

This study evaluates the genotoxic potential of two Ru(III) complexes with thiosemicarbazone based ligands. The complexes were tested for in vitro protective effect on chromosome aberrations in peripheral human lymphocytes using the cytokinesis block micronucleus (CBMN) assay at concentrations 1.5; 3.7 and 7.4 μg/mL. The cell culture treated with the tested complexes, at 3.7 μg/mL concentration, decreased a frequency of micronucleus for 37% and 32%, when compared with the control cell cultures. At concentration of 7.4 (1.5) μg/mL of this complexes exhibited slightly lower effect of micronucleus for 30% (35%) and 27% (29%), when compared with the control cell cultures.

This study evaluates the genotoxic potential of two Ru(III) complexes with thiosemicarbazone based ligands. The complexes were tested for in vitro protective effect on chromosome aberrations in peripheral human lymphocytes using the cytokinesis block micronucleus (CBMN) assay at concentrations 1.5; 3.7 and 7.4 μg/mL. The cell culture treated with the tested complexes, at 3.7 μg/mL concentration, decreased a frequency of micronucleus for 37% and 32%, when compared with the control cell cultures. At concentration of 7.4 (1.5) μg/mL of this complexes exhibited slightly lower effect of micronucleus for 30% (35%) and 27% (29%), when compared with the control cell cultures.

In this study, novel hexa coordinated ruthenium(III) complex of the type Na[RuCl2L2)] (where L = monobasic bidentate Schiff base derived from the condensation of 5-nitrosalicyladehyde with aniline) has been synthesized and characterized by electrospray ionization time-of-flight mass spectrometry, infrared spectroscopy and ultraviolet/visible spectrophotometry. Schiff base N-phenyl-5-nitrosalicylideneimine is coordinated to the ruthenium via imine nitrogen and phenolic oxygen. Mass spectra showed molecular ion (M-) at m/z 653.9641 which corresponds to [C26H18Cl2N4O6Ru]. The in vitro antimicrobial properties of the Schiff base and the complex were tested by micro-dilution technique and agar plate assay for determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). The compounds showed a higher antibacterial activity against tested Gram-positive bacteria (Staphylococcus aureus ATCC 33591 and ATCC 29213), whereas against the Gram-negative bacteria (Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 700603) were ineffective. The genotoxic effects of Ru(III) complex were investigated using the Cytokinesis Block Micronucleus (CBMN) assay in human lymphocytes cultures. The cell culture treated with the complex at a concentration of 3.7 μg/mL exhibit the most prominent effect of decreasing the frequency of micronucleus for 44%, while at the concentrations of 1.5 and 7.4 μg/mL effect is slightly lower (40%), compared to the control cell culture.